Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis

Yong Wang, Guoqiang Xie, Yuanhang Huang, Han Zhang, Bo Yang, Zhiguo Mao*

1 Division of Hemodialysis, CPLA 422 Hospital, Guangdong, China, 2 Kidney Institute of CPLA, Division of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China, 3 Division of Nephrology, General Hospital of Guangzhou Military Region, Guangdong, China, 4 Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

These authors contributed equally to this work.

* maozhigu093@126.com

Abstract

Background
High levels of serum phosphorus both at baseline and during follow-up are associated with increased mortality in dialysis patients, and administration of phosphate binders was independently associated with improved survival among hemodialysis population. Calcium-based phosphate binders are the most commonly used phosphate binders in developing countries for their relatively low costs.

Objectives
To compare the efficacy and safety between calcium carbonate and calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

Methods
PubMed, EMBASE, Cochrane Library, Google scholar and Chinese databases (Wanfang, Weipu, National Knowledge Infrastructure of China) were searched for relevant studies published before March 2014. Reference lists of nephrology textbooks and review articles were checked. A meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs that assessed the effects and adverse events of calcium acetate and calcium carbonate in adult patients with MHD was performed using Review Manager 5.0.

Results
A total of ten studies (625 participants) were included in this meta-analysis. There was insufficient data in all-cause mortality and cardiovascular events for meta-analysis. Compared with calcium carbonate group, the serum phosphorus was significantly lower in calcium acetate group after 4 weeks’ administration (MD -0.15 mmol/L, 95% CI -0.28 to -0.01) and after 8 weeks’ administration (MD -0.25 mmol/L, 95% CI -0.40 to -0.11). There was no difference
in serum calcium levels or the incidence of hypercalcemia between two groups at 4 weeks and 8 weeks. No statistical difference was found in parathyroid hormone (PTH) levels or serum calcium by phosphorus (Ca x P) product. There was significantly higher risk of intolerance with calcium acetate treatment (RR 3.46, 95% CI 1.48 to 8.26).

Conclusions
For hyperphosphatemia treatment, calcium acetate showed better efficacy and with a higher incidence of intolerance compared with calcium carbonate. There are insufficient data to establish the comparative superiority of the two calcium-based phosphate binders on all-cause mortality and cardiovascular end-points in hemodialysis patients.

Introduction
Serum phosphorus in chronic kidney disease (CKD) patients accumulates with the decrease of glomerular filtration rate (GFR), which cause secondary elevation of parathyroid hormone (PTH) level and consequently reduces calcitriol concentration by inhibiting its secretion and promoting its metabolism. A growing body of evidence proved the correlation between elevated serum phosphorus, PTH and calcium in CKD patients, and increased morbidity, mortality, hospitalization rate, cost of care, as well as reduced quality of life.[1]

Phosphate binders, including non-calcium-based phosphate binders and calcium-based phosphate binder, are widely used to lower serum phosphorus levels in CKD patients and prospective cohort study proved that treatment with phosphorus binders was independently associated with improved survival among incident hemodialysis patients.[2] A meta-analysis[3] and an observational cohort study[4] recently shown non-calcium-based phosphate binders slight superior to calcium-based phosphate binders on mortality reduction in CKD patients. However, in developing countries, non-calcium-based phosphate binders (sevelamer and lanthanum carbonate) are not easily available for their high prices, and calcium carbonate and calcium acetate remain to be the most commonly used phosphate binders.[5,6] Several clinical trials and reviews compared calcium acetate and calcium carbonate in efficacy and safety issues, but no clear recommendation has been published between these two options. The aim of this meta-analysis was to assess the efficacy and adverse events of calcium-based phosphate binders (calcium acetate and calcium carbonate) in hemodialysis patients. The following items were investigated in details:

1. Mortality, cardiovascular events and fracture in patients treated with calcium acetate and calcium carbonate;
2. The serum phosphorus lowering effect of calcium acetate and calcium carbonate;
3. The impact of phosphate binders on biochemical parameters such as PTH, serum calcium, phosphorus, and Ca x P product;
4. The incidence and characteristics of the adverse events and the withdraw related to treatment of calcium acetate and calcium carbonate.

Methods
This study was registered at PROSPERO (http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42014009636). CRD42014009636. The authors
Calcium Containing Phosphate Binder for Hyperphosphatemia

search the databases published in English (PubMed, EMBASE, Cochrane Library, Google scholar) and in Chinese (Wanfang, Weipu, National Knowledge Infrastructure of China) before March 2014. “Calcium acetate, calcium carbonate and dialysis/hemodialysis” was the basic search keywords, and the related studies and the references of literatures were checked to expand the search.

Inclusion and excluding criteria for considering studies for this review:

Inclusion criteria

1. Types of studies: randomized controlled trials (RCTs) and the first phase of randomized cross-over studies was included. Studies published in English and Chinese were included.

2. Patients: CKD Patients on hemodialysis and older than 18 years.

3. Intervention: Compared calcium acetate and calcium carbonate for controlling hyperphosphatemia in hemodialysis patients.

Exclusion criteria

1. The participants of studies were at predialysis status or patients with kidney transplant or patients with peritoneal dialysis;

2. Retrospective, as well as nonparallel studies, were excluded.

Study selection

Two reviewers (Y. Wang and G. Xie) independently assessed the eligibility of each article to be included in this meta-analysis, and this work was checked by another author (Z. Mao).

Data collection process and data items

Data were extracted from each identified trial by two researchers (G. Xie and H. Zhang) with a predesigned review form (Microsoft Office Excel 2007) independently, and any disagreement was resolved by discussion. Authors of the original studies were consulted through emails for suggestions if any questions regarding the original study occurred.

The following data were extracted:

1. Basic information of studies: The authors of study, the year of publication, the design, duration and the sample size of the trials, the age and gender of the patients, dialysis model, withdraw rate;

2. The interventions: The dose and usage calcium acetate and calcium carbonate, dialysis model and time, dialysate calcium concentration;

3. Treatment effect: All-cause mortality, cardiovascular mortality, cardiovascular events and incidence of fracture; Serum phosphorus (mmol/L), serum calcium (mmol/L), Ca x P product (mmol²/L²), PTH (pg/mL);

4. Side effects: Incidence and nature of treatment-related adverse effects including gastrointestinal (gastritis, diarrhea, constipation and abdominal bloating), hypercalcemia and dropout related to treatment intolerance.

Risk of bias

The quality of included studies were evaluated by two authors (Y. Bo and G. Xie) independently based on the standard criteria (randomization, allocation concealment, blinding, and loss to
follow-up) using the modified Jadad (highest 7 points) scoring system.[7] The following were quality scoring items: (1) Was the random series generated properly? (2 = Properly with detailed description of randomization, 1 = randomized but detail not reported, 0 = inappropriate); (2) Was the allocation concealment used? (2 = Properly used, 1 = used but without details, 0 = not used) (3) Was the blinding method used? (2 = Double-blind, 1 = single-blind, 0 = open-label); (4) Were dropout and follow-up reported? (1 = Numbers and reasons reported, 0 = not reported). The publication bias was assessed by examining the funnel plot. A sensitivity analysis was performed by omitting studies one by one and investigating the influence on the overall meta-analysis estimate.

Data analysis and statistical methods
Statistical analyses were performed with Review Manager 5.0.20 (Cochrane Collaboration, Oxford, UK). We assessed the heterogeneity of the trial results by calculating a chi-square test of heterogeneity and the $I^2$ measure of inconsistency. Dichotomous data were summarized as risk ratio (RR) and 95% confidence intervals (CIs), continuous ones as weighted mean difference (WMD) and 95% CIs as well. Random effects model was used in all analysis.

Results
Study characteristics
The flow chart of including and excluding literatures was shown in Fig. 1 (Flow Diagram). After screening the abstract and excluding the studies clearly not meet the inclusion criteria, 42 full-text were obtained. Of these, 32 articles were excluded for the following reasons: 1) Participants were not hemodialysis patients (n = 5); 2) Study design were not parallel controlled study (n = 3) or without randomization(n = 7); 3) Without comparing the serum phosphorus lowering effect between calcium acetate and calcium carbonate (n = 13); 4) There were 4 studies excluded: the dose of phosphate binders were adjust to the serum phosphorus concentration (n = 3)[8–10], and not a clinical RCT (n = 1)[11]. A total of ten studies[12–21] (625 participants) were included from 260 articles retrieved. The follow up period was 4 weeks to 48 weeks and the most common phosphate binder administration period was 4 or 8 weeks. The participants were on hemodialysis for 2 to 3 times per week with the dialysate calcium concentration range from 1.25 to 1.75 mmol/L. There were 4 studies[18–21] designed as crossover trials and only 2 studies[18,20] designed as double blind. The other 6 studies are randomized open parallel controlled trials. The modified Jadad score systerm shown 4 studies[17–20] with high quality (> = 4 points). The characteristics and quantities of the studies were shown in Table 1.

Effects of interventions
Clinical outcomes. A total of 5 patients died after study’s randomization. Planz et al[19] reported 3 cases death all occurred on calcium acetate treatment period (crossover study): One had long-standing malignant disease, not associated with hypercalcaemia, one died of postoperative complications following a thoracotomy and the third suffered a myocardial infarction. Lu Rh et al[13] reported 2 cases of death: One in calcium acetate group suffered from sudden death and the other in calcium carbonate group died for lung infection. There was no data on fracture and cardiovascular events except the death caused by myocardial infarction. Serum phosphorus Compared with calcium carbonate group, there was a significant lower serum phosphorus value in calcium acetate group after 4 weeks’ treatment (4 studies, 196 participants:...
Serum calcium.

There was no difference in serum calcium concentration between two groups after 4 weeks' administration (5 studies, 319 participants, MD 0.03 mmol/L, 95% CI-0.15 mmol/L, 95% CI-0.28 to-0.01, Fig. 2A) and 8 weeks (8 studies, 523 participants: MD-0.25 mmol/L, 95% CI-0.40 to-0.11, Fig. 2B) respectively.

Serum calcium. There was no difference in serum calcium concentration between two groups after 4 weeks' administration (5 studies, 319 participants, MD 0.03 mmol/L, 95% CI-
0.01 to 0.07) and after 8 weeks (8 studies, 523 participants; MD 0.00 mmol/L, 95% CI -0.09 to 0.08, Fig. 3).

**Ca x P product and PTH.** There was no statistical difference on serum calcium by phosphorus (Ca x P) product (4 studies, 290 participants: MD -7.58 mmol²/L², 95% CI -17.65 to 11.83  mmol²/L²).

| Trials     | Number | Length     | Mean age (year) | Gender male/female | Dialysis model                  | Dialysate calcium concentration | Elemental calcium dose (mg) | Quality grade |
|------------|--------|------------|-----------------|--------------------|----------------------------------|---------------------------------|----------------------------|---------------|
| Caravaca   | 80     | 16 Weeks   | 48.5            | 45/35              | MHD, (3 times)/week              | 1.62 mmol/L                     | 1500/1500                 | 4             |
| d’Almeida Filho 2000 | 52     | 12 Weeks   | 46              | 26/62              | MHD, (3 times)/week              | 1.75 mmol/L                     | 1400/2500                 | 5             |
| Liu Q 2013 | 60     | 8 weeks    | 50.9            | 38/22              | MHD, 12h/week                    | 1.50 mmol/L                     | 942/900                   | 2             |
| Lu RH 2013 | 171    | 8 weeks    | 53.8/52.1       | 75/48              | MHD, about 12h/week              | 1.25–1.50 mmol/L                | 1000(1500)/1000 (1500)²  | 3             |
| Pflanz 1994| 31     | 12 months  | 59.5            | 21/31              | MHD, 12h/week                    | 1.25 mmol/L                     | 1500/1500                 | 4             |
| Ring 1993  | 21     | 8 Weeks    | 19–75           | 9/6                | MHD, 8–12h/week                  | 1.74 mmol/L                     | 1440(540–2700)            | 5             |
| Saif 2007  | 64     | 12 Weeks   | 42.6            | 24/17              | MHD, (2–3 times)/week            | NC                              | 1014/2250                 | 2             |
| Tao YM 2012| 60     | 8 Weeks    | 47.6            | 34/26              | MHD, 12h/week                    | 1.25 mmol/L                     | 1000/1050                 | 2             |
| Wang CF 2012| 48    | 24 Weeks   | 38              | 30/18              | MHD, 8–12h/week                  | 1.25 mmol/L                     | 1000/1000                 | 2             |
| Zhang M 2013| 38    | 4 weeks    | 41              | 22/16              | MHD, (3 times) 13.5h/week         | 1.25 mmol/L                     | 1064/1200                 | 3             |

Abbreviations: MHD, Maintenance hemodialysis; Elemental calcium dose, Elemental calcium content of phosphate binders; NC, not clear.

* The elemental calcium dose was 1000mg and 1500mg for patients with the serum phosphorus level 1.96–2.26 mmol/L, 2.27–2.75 mmol/L respectively.

**Table 1. Characteristics of the included trials.**
2.49, Fig. 4) and parathyroid hormone (PTH) levels (6 studies, 403 participants: MD-5.00 pg/mL, 95% CI 53.78 to 43.78, Fig. 5) between calcium acetate group and calcium carbonate group after 8 weeks’ administration.

**Side effects**

Dropout related to treatment intolerance. There was a significantly higher incidence of intolerance with calcium acetate treatment (3 studies, 243 participants: RR 3.46, 95% CI 1.48 to 8.26, Fig. 6). Twenty-one of 122 patients (17.2%) in calcium acetate group and 6 of 121 patients (5.0%) in calcium carbonate group dropped out related to drug intolerance respectively.

Treatment-related adverse effects. The most common side effects reported were gastrointestinal symptoms, including epigastrium pain, bloating, nausea and anorexia. There was a trend of higher incidence of adverse gastrointestinal events in calcium acetate treated patients (11.9%) compared with calcium carbonate treated patients (5.7%), but the difference was not statistical significant (4 studies, 351 participants: RR 1.96, 95% CI 0.91 to 4.19). All side effects including gastrointestinal events were mild and easy to be treated.

Hypercalcemia. There were 6 studies, involved 530 patients, reported the incidence of hypercalcemia. There was no significant difference for the incidence of hypercalcemia (RR 0.77, 95% CI 0.46 to 1.29, Fig. 7) between calcium acetate group (24/261, 9.2%) and calcium carbonate group (30/269, 11.2%).

**Heterogeneity and sensitivity analysis**

The funnel plots (Fig. 8A) showed significant visual asymmetry. The heterogeneity was observed in some analysis. Covariates including measures of study quality (blinding and
intention-to-treat analysis), patient characteristics (baseline PTH, calcium and phosphorus concentration), and study characteristics (medication dose and study duration) were significant effect modifiers on some outcomes. We explored the potential sources of heterogeneity using subgroup analysis. However, data were insufficient to allow definitive conclusions to be drawn. For the comparison of serum phosphorus after 8 weeks' administration, we found that the serum phosphorus did not change (from 2.28 to 2.30 mmol/L) after treatment in calcium carbonate group in one study[16], which was difficult to explain. So the authors tried to exclude this study in the serum phosphorus comparison, and the heterogeneity disappeared without changing the superior effect of calcium acetate. After exclusion of that trial mentioned above, the funnel plots (Fig. 8B) did not show significant visual asymmetry. Heterogeneity was observed in PTH value comparison ($I^2 = 89\%$), the authors found that the value of serum PTH was obviously lower in Caravaca’s study.[17] So the authors tried to exclude this study in that analysis, the heterogeneity disappeared. Omitting studies one by one showed that the overall meta-analysis estimate would not be turned over by excluding any study.

**Discussion**

**Summary of results and possible explanations**

Serum calcium, inorganic phosphate and calcium phosphate product levels are associated with worse outcomes in patients with CKD.[1,22] Ca, P and calcium by phosphate product are useful additional variables when determining risk in chronic heart failure dialysis patients.[23] A prospective cohort study of 10,044 incident hemodialysis patients shown that treatment with phosphorus binder was independently associated with decreased mortality compared with no treatment in the intention-to-treat, as-treated, and matched analyses.[2]

This meta-analysis compared the effects and side effects of two most commonly used calcium-based phosphate binders, calcium acetate and calcium carbonate, in hemodialysis patients.
patients. To our best knowledge, this in-depth comparison involved the largest participant sample size. All-cause mortality and cardiovascular events are the final and the most important indexes for the effect and side effect of phosphate binders, however, the data were insufficient to make conclusions in our analysis as well as in other reviews. This was might due to the short-term follow-up, which is difficult to show the difference on mortality and cardiovascular events. On the other hand, our review shown that 8 weeks’ administration of phosphate binders was enough to control hyperphosphatemia. (Fig. 2B)

Our review revealed that calcium acetate was more effective in reducing serum phosphorus level compared with calcium carbonate, and no difference was seen in serum calcium and PTH concentration. Although the element calcium was equal or higher in calcium carbonate group, the serum phosphorus was 0.15 mmol/L lower in calcium acetate group after an 4-week administration and 0.25 mmol/L lower after 8 weeks. This results showed the stronger effect of calcium acetate in lowering serum phosphorus, which was consistent with the previous trial comparing the doses and durations of calcium acetate and calcium carbonate in achieving the target of control serum phosphorus in hemodialysis patients and consistent with the theoretical and in vitro study investigating the effect of phosphate binders in inhibiting dietary phosphorus absorption in normal subjects. In a previous meta-analysis, comparison between these two calcium containing phosphate binders showed no statistical difference in reducing phosphorus

![Figure 7](https://doi.org/10.1371/journal.pone.0121376.g007)

**Fig 7.** The incidence of hypercalcaemia in calcium-based phosphate binder groups.

![Figure 8](https://doi.org/10.1371/journal.pone.0121376.g008)

**Fig 8.** Significant visual asymmetry was revealed by the funnel plots (A) and the visual asymmetry disappeared after excluding one study with unreasonable results (B).
level, and a small participants number involved (only 143) might attenuate the power to reveal the difference.[24]

The main side effects of both agents were gastrointestinal symptoms, including epigastrium pain, bloating, nausea and anorexia. There was a trend of higher incidence of adverse gastrointestinal events in calcium acetate group and that might lead to the higher incidence of treatment intolerance of calcium acetate. Those most reported symptoms related to the two agents disappeared after treatment withdrawal. Another announced side effect was agents relating to hypercalcaemia, our review showed hypercalcaemia occurring in 9.2% of patients in calcium acetate group and 11.2% in calcium carbonate group, without significant difference.

Limitations of this review

Limitations of the present study including a short-term study duration (4 weeks to 12 months), the language of studies were limited to English and Chinese and studies in other languages might be missed, a small number of studies with blinding (only two trials)[18,20], relatively small number of participants (625 in total) and insufficient data on all-cause mortality and cardiovascular events. The heterogeneity and asymmetry of funnel plots was observed in the analysis, possible reasons might include the differences of study design and baseline information of participants.

Conclusions

Based on meta-analysis of RCTs and first phase of randomized crossover studies, calcium acetate showed better effect on hyperphosphatemia control than calcium carbonate, but with a relative higher incidence of intolerance. There are insufficient data to establish the comparative superiority of the two calcium-containing phosphate binders for all-cause mortality and cardiovascular end-points in hemodialysis patients.

Supporting Information

S1 PRISMA Checklist.

(DOC)

Author Contributions

Conceived and designed the experiments: YW GX YH ZM. Analyzed the data: BY GX. Wrote the paper: YW HZ ZM. Searched the databases: YW YH. Study inclusion: YW GX ZM. Data collection: GX HZ. Critical revision of the manuscript for important intellectual content: GX ZM.

References

1. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008; 52: 519–530. doi: 10.1053/j.ajkd.2008.03.020 PMID: 18514987
2. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20: 388–396. doi: 10.1681/ASN.2008060609 PMID: 19902121
3. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013; 382: 1268–1277. doi: 10.1016/S0140-6736(13)60897-1 PMID: 23870817
4. Yusuf AA, Weinhandl ED, St PWL. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in medicare part d. Am J Kidney Dis. 2014; 64: 95–103. doi: 10.1053/j.ajkd.2013.11.015 PMID: 24387795

5. Afifi E, El-Sayed H, El-Setouhi M, Ahmed H, Khalifa N. Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue. Hemodialysis international. International Symposion on Home Hemodialysis. 2005; 9: 409–415. PMID: 16219062

6. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010; 362: 1312–1324. doi: 10.1056/NEJMoa0912522 PMID: 20375408

7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996; 17: 1–12. PMID: 8721797

8. Janssen MJ, van der Kuy A, ter WPM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol. 1996; 45: 111–119. PMID: 8846523

9. Emmett M, Simron MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991; 17: 544–550. PMID: 2024656

10. Almirall J, Veciana L, Libre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol. 1994; 14: 192–196. PMID: 7977479

11. Mai ML, Emmett M, Sheikh MS, Santa ACA, Schiller LR, Fordtran JS. Calcium acetate, an effective phosphate binder in patients with renal failure. Kidney Int. 1989; 66: 856–860. PMID: 2811066

12. Tao YM, Liang LX, Wang WJ, Liu SX. Efficacy of combined physiological calcium dialysate with calcium acetate for hyperphosphatemia in hemodialysis patients. The Journal of Practical Medicine. 2011; 27: 4008–4009.

13. Wang CF, Xia Y. Efficacy of combined low calcium dialysate with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Chinese Journal of Practical Medicine. 2012; 39: 96–97.

14. Zhang M, Gu BX, Gao CF, Gao X. Calcium acetate versus calcium carbonate as phosphate binders for hemodialysis patients. Clinical Medicine of China. 2013; 29: 1286–1288.

15. Lu RH, Ni ZH, Qian JQ, Zhang Z. Safety and efficacy of calcium acetate in the treatment of hyperphosphatemia of haemodialysis patients. Chin J Nephrol. 2013; 29: 429–434.

16. Liu Q. Short-term efficacy of calcium acetate and calcium carbonate for hyperphosphatemia in patients with maintenance hemodialysis. Zhejiang Medicine Journal. 2013; 39: 672–674. doi: 10.1136/medethics-2013-101815 PMID: 24129789

17. Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron. 1992; 60: 423–427. PMID: 1584317

18. Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrol Dial Transplant. 1993; 8: 341–346. PMID: 8390009

19. Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant. 1994; 9: 1121–1124. PMID: 7800211

20. d’Almeida FEJ, da CEA, Hoette M, Ruzany F, Keen LN, Lugon JR. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Sao Paulo medical journal = Revista paulista de medicina. 2000; 118: 179–184. PMID: 11120549

21. Saif I, Halim A, Altuf A, Saif M, Khalid M, Ahmad D, et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. J Ayub Med Coll Abbottabad. 2007; 19: 26–28. PMID: 18693591

22. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607–617. PMID: 9531176

23. Cubbon RM, Thomas CH, Drozd M, Gierula J, Jamil HA, Byrom R, et al. Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure. J Nephrol. 2014.

24. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011; CD0006023. doi: 10.1002/14651858.CD0006023.pub2 PMID: 21328279

25. Almirall J, Veciana L, Libre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol. 1994; 14: 192–196. PMID: 7977479

26. Sheikh MS, Maguire JA, Emmett M, Santa ACA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphate binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989; 83: 66–73. PMID: 2910921